Raynaud disease
Drug research and approvals for raynaud disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of raynaud disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic SclerosisNCT07360808 · Not applicable · Cytori Therapeutics · starts Dec 31, 2025
- POLish Registry of CArdioneuroablation and CArdioneuromodulationNCT07196397 · Not reported · SABAMED Medical Center Ltd. · starts Nov 21, 2024
- Open Label Treprostinil Raynaud's StudyNCT07112183 · Phase 4 · Brigham and Women's Hospital · starts Oct 15, 2025
- Multi-modal Quantitative Imaging of the SkinNCT06989216 · Not reported · HJN Sverige AB/Neko Health · starts Feb 1, 2023
- The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeNCT06675344 · Not applicable · Robyn T. Domsic, MD, MPH · starts Jan 6, 2025
- Preventive Effect of Clopidogrel on the Systemic Sclerosis Development RiskNCT05098704 · Phase 2 / Phase 3 · University Hospital, Bordeaux · starts Jun 22, 2022
Phase 3 8
- NitroglycerinSoluble guanylate cyclase activator
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- TadalafilPhosphodiesterase 5A inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- IloprostProstanoid IP receptor agonist
- NifedipineVoltage-gated L-type calcium channel blocker
- Lactose,
- st. john's wort
Phase 2 5
- RiociguatSoluble guanylate cyclase positive allosteric modulator
- VardenafilPhosphodiesterase 5A inhibitor
- AmlodipineVoltage-gated L-type calcium channel blocker
- UdenafilPhosphodiesterase 5A inhibitor
- PF-00489791Phosphodiesterase 5A inhibitor
How its trials ended
79 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 37% met their primary endpoint, 21% missed it and 42% stopped early.
- Completed, result not reported4456%
- Status unknown1013%
- Met its primary endpoint79%
- Ongoing68%
- Stopped: other or unclear56%
- Missed its primary endpoint45%
- Stopped: sponsor or business decision23%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA